Compare Novartis AG (NVS) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard S&P 500 ETF — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Vanguard S&P 500 ETF trades at $714.32 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 6.6× Novartis AG's market cap, and Novartis AG pays a 3.31% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard S&P 500 ETF for 55 Days on average.
| NVS | VOO | |
|---|---|---|
Market Cap | $274.00B | $1.80T |
Volume | 1,852,137 | 4,660,398 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $716.17 |
52-Week Low | $121.80 | $580.93 |
Typical Hold Time | 82 Days | 55 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
VOO trades at $714.42, down 0.24% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF's dividend yield is modest, and recent news highlights its role in long-term wealth building amid expectations of slowing S&P 500 profit growth. Short interest increased 46.9% in September, indicating some bearish sentiment.
The outlook for VOO remains positive for buy-and-hold investors, supported by its low-cost exposure to the S&P 500. Risks include macroeconomic headwinds from potential Fed rate hikes and elevated short interest. Analyst consensus favors long-term holding, with the ETF seen as a core portfolio component for diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
